** Shares of Lucid Diagnostics LUCD.O down 18.1% at $1.04 premarket after $25 mln follow-on prices

** New York City-based cancer prevention firm announces selling 25 mln shares at $1

** Offering price represents ~21% discount to stock's last close

** The PAVmed Inc PAVM.O subsidiary plans to use net proceeds for working capital, general purposes

** Canaccord Genuity and BTIG are joint bookrunners for the offering

** Lucid has ~108.5 mln shares outstanding for $138 mln market cap

** Its flagship product, the EsoGuard Esophageal DNA Test, is used to screen for esophageal precancer and cancer in at-risk gastroesophageal reflux disease patients

** Through Tues, shares gained 55% YTD

** All 6 analysts are bullish on LUCD and median PT is $3, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))